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A pathy was initially conceptualized by stoic philosophers as a desirable and virtuous state of the soul, free from the harmful influence of passions. However, during the nineteenth century, at the inception of modern psychiatric nosology, apathy turned to be regarded as a morbid negative state affecting free will, intellectual capacity, and emotional responsiveness. 1 In 1991, Marin formulated apathy as an independent neuropsychiatric syndrome. He described the phenomenological aspects of apathy around the concepts of reduced goal-directed behaviour (as manifested by lack of effort, initiative, and productivity), reduced goal-directed cognition (as manifested by decreased interests, lack of plans and goals, and lack of concern about one's own health or functional status), and reduced emotional concomitants of goal-directed behaviours (as manifested by flat affect, emotional indifference, and restricted responses to important life events). However, it is unclear if changes in emotional experience and emotional expression should be considered an essential component of apathy or if this can occur independently of anhedonia and blunted emotional reactivity. Other investigators have questioned whether the psychological concept of motivation is appropriate to describe the behavioural changes observed after brain damage. 2 These investigators emphasize that the lack of spontaneity observed among apathetic patients can be reverted by external cues. 2 In this sense, constructs such as the auto-activation deficit 3 and athymhormia 4 describe pathological states in which patients are incapable of self-initiating goal-directed activities but respond normally to behavioural prompting.
There are different instruments to assess the presence of apathy. In the early 1990s, Marin and colleagues 5,6 developed the Apathy Evaluation Scale, an 18-item scale that can be administered as a self-rated scale, as a caregiver paper-and-pencil test, or as a clinician-administered test. The scale provided a conceptual framework for the diagnosis of apathy and a reliable measure of its severity. In the following years, although other instruments were designed to assess the frequency and severity of apathetic symptoms, 7-10 there was not a clear formulation of specific diagnostic criteria. Starkstein et al 11 have recently proposed a set of criteria along with a structured interview to diagnose apathy in dementia. The structured interview includes questions assessing the lack of motivation domains relative to a person's previous level of functioning, lack of effort to perform ADL, dependency on others to structure activity, lack of interest in learning new things or in new experiences, lack of concern about one's personal problems, unchanging or flat affect, and lack of emotional response to positive or negative personal events (Table  1) . However, as we gradually move into the DSM-V nomenclature, there is a need for further discussion and consensus on the defining characteristics of apathy as a syndrome.
Apathy is more frequent among people with some degree of cognitive impairment, such as may be observed among patients with stroke, Alzheimer disease, or Parkinson disease. 7, 12, 13 Consistently, most studies assessing apathy in various neurological disorders reported relatively low MMSE scores for patients with apathy, 14 compared with those who are not apathetic.
However, cognitive deficits are not sufficient to produce apathy, given that a significant proportion of people with moderate or severe dementia do not show apathy. 15, 16 Similarly, although apathy is more frequent among patients with depressive disorders, particularly major depression, they should be considered as distinct syndromes with different clinical features as well as prognostic and treatment implications. 17 Further, apathy and disinhibition could alternate in the same person. In fact, several studies demonstrated a significant association between apathy and disinhibition in patients with dementia. 18, 19 Methods This review will focus on apathetic syndromes observed following stroke. We have explored relevant databases (that is, PubMed, MEDLINE, and PsycINFO) using the following key words and their combinations: apathy, motivation, abulia, stroke, cerebrovascular disease, basal ganglia, prefrontal cortex, anterior cerebral infarction, and thalamus. In addition, we have explored the references cited in the articles retrieved by our original search.
Apathy in Stroke
Apathy has been consistently described among patients with cerebrovascular disease. Starkstein et al 12 examined the frequency and correlates of apathy in a series of 80 patients with stroke. Using a cut-off score of 12 on the Apathy Scale (an abridged version of the Apathy Evaluation Scale), Starkstein et al 12 found that 18 of 80 consecutive patients (22.5%) admitted to hospital with an acute cerebrovascular lesion met this criterion for apathy. Among the 18 patients with apathy, 9 (50%) had associated major or minor depression. Poststroke apathy was also significantly associated with older age, cognitive impairment, and impairment in ADL, as well as lesions of the posterior limb of the internal capsule. 12 Angelelli et al 20 administered the Neuropsychiatric Inventory to a group of 124 stroke patients, divided into 3 groups on the basis of time from stroke (2, 6, and 12 months) and to 61 healthy subjects. Apathy was significantly more frequent among stroke patients. It was diagnosed in 33 patients (27%), and depressive disorder was diagnosed in 76 patients (61%). 20 In this series, apathy was more frequent in the chronic phase (that is, at 6 and 12 months) than in the subacute stage. There were no significant associations with the severity of impairment and stroke location. 20 Brodaty et al 21 compared the frequency and correlates of apathy among 135 patients with ischemic stroke and 109 control subjects matched for sex and age. Patients were assessed 3 to 6 months after their stroke. Apathy was diagnosed in 26.7% of stroke patients, compared to 5.4% of control subjects. Consistent with previous results, apathetic stroke patients were older, more functionally dependent, and more cognitively impaired than those without apathy. There was not significant correlation between apathy and depression as diagnosed by a clinical interview. Apathy was not related to the type, location, volume, or severity of stroke. However, apathetic patients were more likely to present right frontal lesions. 21 Hama et al 22 used the Neuropsychiatric Inventory to assess the frequency of depression and apathy among 237 Japanese stroke patients. Depression was observed in 88 patients (40.2%) and apathy in 42 (19.2%). In addition, they examined whether severity of depressive or apathetic symptoms had a negative impact on ADL recovery measured by the NAA-Cr N-acetylaspartate-creatine ratio rCBF regional cerebral blood flow FIM. Multiple regression analysis revealed that, in this sample of stroke patients, the severity of apathetic symptoms but not the severity of depressive symptoms was inversely correlated with improvement in FIM. 22 These investigators also analyzed the relation between the presence of apathy and depression and the location of stroke. The severity of depressive symptoms was associated with left frontal lobe (but not basal ganglia) damage, while the severity of apathetic symptoms was related to damage to the bilateral basal ganglia (but not to the frontal lobe). 23 Santa et al 24 examined the frequency of apathy among 67 stroke patients within 3 months after their first ischemic or hemorrhagic stroke, excluding those with dementia or significant aphasia. From the Apathy Scale, 14 patients (21%) were diagnosed as being apathetic. The apathetic patients were older and more cognitively impaired than patients without apathy. In addition, following rehabilitation therapy, apathetic patients showed less improvement in physical disability and functional independence than nonapathetic patients. 24 In summary, the frequency of apathy following stroke has been consistently estimated between 20% and 25%. It appears to be associated with the presence of cognitive impairment, a chronic course characterized by progressive functional decline, and with disruption of basal ganglia circuits.
Pathophysiological Aspects
Previous studies suggest an association between apathy following stroke and damage to frontal-subcortical networks. For instance, Starkstein and Manes 25 reported that apathy was associated with the presence of internal capsule lesions involving the pallidal and nigral output to the thalamus. In a classic paper, Bhatia and Marsden 26 reviewed the behavioural and movement disorders reported in 240 patients with lesions affecting the caudate nucleus, putamen, and the globus pallidus. They found that apathy (abulia) was observed in 30 patients (13%). Lesions of the caudate nucleus were more likely to cause significant apathetic symptoms. These were observed among 18 of 64 (28%) patients with caudate lesions, 15 of which were unilateral. Conversely, apathy was not observed with lesions of the putamen, suggesting that lesions of the motor loop do not produce significant motivational changes. 26 Ischemic lesions of the anterior cerebral artery territory have been also associated with apathy. 27 A recent study 28 of a 100 patients with anterior cerebral artery infarction found that 43 patients presented with hypobulic syndromes. Apathy was related to lesions located in the fontal pole, cingulate gyrus, and superior medial frontal gyrus. It also occurred more frequently in patients with bilateral lesions, followed by left-sided lesions. 28 In addition, apathy may be a prominent feature of thalamic strokes, particularly those involving the territory of the paramedian arteries, including the dorsomedian and intralaminar thalamic nuclei. 29 Overall, these findings suggest that apathy is related to the disruption of neural networks connecting the anterior cingulate gyrus, the dorsomedial frontal cortex, and the frontal pole with the ventral aspects of the caudate nucleus, the anterior and ventral globus pallidus, and the dorsomedian and intralaminar thalamic nuclei. However, functional studies probing the integrity of these circuits in apathetic stroke patients have been rare and showed contradictory results. For instance, Okada et al 30 examined the relation between rCBF and severity of apathetic symptoms in 40 elderly stroke patients (mean age, 71.4 years), one-half of whom showed apathy. The apathetic group showed a significantly reduced rCBF in the right dorsolateral frontal and left frontotemporal regions. Moreover, apathy scores were negatively correlated with rCBF in the same regions. 30 In addition, a recent study 31 used single voxel proton magnetic resonance spectroscopy to compare frontal lobe NAA-Cr ratios between 31 patients with ischemic stroke that did not involve the frontal lobes and 20 healthy subjects. Among the 31 patients, 13 (42%) presented an apathetic syndrome. NAA-Cr ratios were significantly reduced in the right frontal lobes of apathetic patients with left-sided brain lesions, suggesting a laterality effect. 31 Another study 32 examined novelty processing in a group of stroke patients with and without apathy. Processing of novel events was quantitated by the latency and amplitude of brain-evoked potentials elicited by task-irrelevant novel W La Revue canadienne de psychiatrie, vol 55, no 6, juin 2010 352
In Review Table 1 
Diagnostic criteria for apathy (adapted from Marin 50 )
A. Lack of motivation relative to the patient's previous level of functioning or the standards of his or her age and culture as indicated either by subjective account or observation by others.
B. Presence, while with lack of motivation, of at least 1 symptom belonging to each of the following 3 domains: stimuli (novelty P3). The apathetic group was more cognitively impaired and showed significantly prolonged and reduced novelty-related potentials over the frontal lobe, suggesting that P3 is a useful physiological measure for apathy following stroke. 32 Finally, Schmidt el al 33 studied graded motor responses from 13 patients with bilateral basal ganglia lesions and AAD and 13 patients with Parkinson disease in their off state. They developed a behavioural paradigm contrasting the force levels elicited to squeeze a hand grip as a result of externally driven cues to the force levels generated through a self-driven task based on the expectation of different monetary rewards. Patients with AAD did not differ from patients with Parkinson disease in motor responses to external instructions or affective response to monetary incentives assessed by skin conductance tests. However, unlike the changes observed in patients with Parkinson disease, they failed to vary their grip force according to the different monetary incentives. The authors concluded that although AAD patients had preserved motor control and normal affective appraisal of positive rewards, they were unable to integrate their expected value into their motor output. 33 Interestingly, this impairment appears to be unrelated to dopaminergic deficiency.
Treatment
Despite a growing interest in apathy, published treatment studies [34] [35] [36] [37] have been mostly limited to anecdotal case reports, generally using dopamine agonists or stimulant medications. For instance, a patient with prominent apathy secondary to multiple subcortical infarcts was treated successfully with methylphenidate. 38 Single photon emission computed tomography and reaction time testing showed selective improvement of frontal system function. 38 Whyte et al 39 examined the effect of acetylcholinesterase inhibitors on functional recovery from ischemic stroke. Participants received galantamine (maximum dose, 24 mg/day) or donepezil (maximum dose, 10 mg/day) for 12 weeks. Donepezil-treated participants experienced a 14-point greater improvement in the FIM motor score, compared with either galantamine-treated participants or an historical comparator group. Change in apathy, but not in cognition, was also associated with change in the FIM motor score. 39 Nefiracetam is a novel cyclic gamma-aminobutyric compound that has been demonstrated in animal studies to enhance aminergic, glutamatergic, and cholinergic neurotransmission by stimulating alpha-4, beta-2 type neuronal nicotinic acetylcholine receptors. [40] [41] [42] [43] [44] [45] In addition, nefiracetam increased brain-derived neurotrophic factor expression as well as rCBF and glucose use after sustained cerebral ischemia in rats. 46, 47 Robinson et al 48 have conducted a 12-week randomized double-blind, placebo-controlled trial assessing the efficacy of nefiracetam for treatment of poststroke depression. Within 3 months of an index stroke, 159 patients with major depression were randomly assigned to receive placebo, 600 or 900 mg nefiracetam, and evaluated at 4, 9, and 12 weeks using the 17-item version of the Hamilton Depression Rating Scale 49 as the primary outcome measure. Robinson et al 48 found that nefiracetam was not more efficacious than placebo in treating depressive disorder. 48 This was largely due to a high placebo response in this group of stroke patients. However, Robinson et al 48 performed a secondary analysis of this trial focusing on the efficacy of nefiracetam, compared with placebo, in treating apathy following stroke. Among the 137 patients who had at least 4 weeks of treatment, 70 patients (51.1%) met diagnostic criteria for apathy as well as major depression owing to stroke. Robinson et al 48 found that poststroke apathy associated with major depression was significantly improved using 900 mg/day of nefiracetam, compared with a lower dose of nefiracetam (600 mg) or placebo. Further studies should assess whether apathy without depression may also respond to this treatment.
In summary, although apathy is a frequent and debilitating condition following stroke, there is a paucity of controlled clinical trials on the efficacy of current therapeutic options such as dopaminergic agents, stimulants, or cholinesterase inhibitors. Other drugs with the potential of modulating neurotransmission in multiple projection systems should also be rigorously tested.
